8.96

2.05% 0.18

After Hours: 8.76 -0.20 -2.23%

Pulmonx Corp (LUNG)

Overview News Price History Option Chain Financials Discussions Forecast

Pulmonx Corp stock is traded at $8.96, with a volume of 1.01M. It is up +2.05% in the last 24 hours and up +44.75% over the past month. Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Previous Close:

$8.78

Open:

$8.91

24h Volume:

1.01M

Relative Volume:

3.67

Market Cap:

$353.81M

Revenue:

$68.68M

Net Income/Loss:

$-60.84M

P/E Ratio:

-5.60

EPS:

-1.6

Net Cash Flow:

$-38.42M

1W Performance:

+28.55%

1M Performance:

+44.75%

6M Performance:

+23.93%

1Y Performance:

-38.21%

1-Day Range:

$8.63

$9.35

1-Week Range:

$6.495

$9.37

52-Week Range:

$5.46

$14.20

Pulmonx Corp Stock (LUNG) Company Profile

Name

Pulmonx Corp

Sector

Healthcare (1169)

Industry

Medical Devices (154)

Phone

650-364-0400

Address

700 CHESAPEAKE DRIVE, REDWOOD CITY

Employee

279

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

LUNG's Discussions on Twitter

Compare LUNG with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LUNG Pulmonx Corp	8.96	353.81M	68.68M	-60.84M	-38.42M	-1.60
ABT Abbott Laboratories	134.92	234.01B	41.95B	13.40B	6.49B	7.65
BSX Boston Scientific Corp	104.49	154.20B	16.75B	1.85B	2.37B	1.25
SYK Stryker Corp	382.78	146.06B	22.60B	2.99B	3.49B	7.76
MDT Medtronic Plc	89.94	115.42B	33.20B	4.26B	5.47B	3.29
EW Edwards Lifesciences Corp	73.30	43.23B	5.72B	4.17B	490.10M	6.97

Pulmonx Corp Stock (LUNG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-11-24	Downgrade	Citigroup	Buy → Neutral
Jun-04-24	Initiated	Lake Street	Buy
Feb-23-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-05-23	Initiated	Craig Hallum	Buy
Feb-27-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-03-23	Downgrade	BofA Securities	Neutral → Underperform
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Jul-11-22	Downgrade	Citigroup	Buy → Neutral
Mar-02-22	Resumed	BofA Securities	Neutral
Dec-08-21	Upgrade	Piper Sandler	Neutral → Overweight
Apr-01-21	Initiated	Citigroup	Buy
Mar-25-21	Initiated	Piper Sandler	Neutral
Mar-10-21	Upgrade	BofA Securities	Neutral → Buy
Jan-04-21	Downgrade	BofA Securities	Buy → Neutral
Oct-26-20	Initiated	BofA Securities	Buy
Oct-26-20	Initiated	Canaccord Genuity	Buy
Oct-26-20	Initiated	Morgan Stanley	Equal-Weight
Oct-26-20	Initiated	Stifel	Buy
Oct-26-20	Initiated	Wells Fargo	Equal Weight

View All

Pulmonx Corp Stock (LUNG) Latest News

Feb 21, 2025

Stock summary: Pulmonx witnessed weekly surge of 20.43% after fourth-quarter earnings exceed expectations - Business Upturn

Feb 21, 2025

Feb 20, 2025

Top 3 Health Care Stocks You May Want To Dump In February - Benzinga

Feb 20, 2025

Pulmonx Corporation (NASDAQ:LUNG) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 20, 2025

Citi raises Pulmonx stock target following record revenue By Investing.com - Investing.com Nigeria

Feb 20, 2025